Eintrag weiter verarbeiten
Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors.
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Blood, 108, 2006, 11, S. 3947-3947 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Loges, Sonja Suhrbier, Karin Otten, Jasmin Riethdorf, Sabine Schuch, Gunter Pantel, Klaus Bokemeyer, Carsten Fiedler, Walter Loges, Sonja Suhrbier, Karin Otten, Jasmin Riethdorf, Sabine Schuch, Gunter Pantel, Klaus Bokemeyer, Carsten Fiedler, Walter |
|---|---|
| author |
Loges, Sonja Suhrbier, Karin Otten, Jasmin Riethdorf, Sabine Schuch, Gunter Pantel, Klaus Bokemeyer, Carsten Fiedler, Walter |
| spellingShingle |
Loges, Sonja Suhrbier, Karin Otten, Jasmin Riethdorf, Sabine Schuch, Gunter Pantel, Klaus Bokemeyer, Carsten Fiedler, Walter Blood Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. Cell Biology Hematology Immunology Biochemistry |
| author_sort |
loges, sonja |
| spelling |
Loges, Sonja Suhrbier, Karin Otten, Jasmin Riethdorf, Sabine Schuch, Gunter Pantel, Klaus Bokemeyer, Carsten Fiedler, Walter 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v108.11.3947.3947 <jats:title>Abstract</jats:title> <jats:p>Angiogenesis and lymphangiogenesis promote tumor growth and metastasis. In addition to vessel sprouting circulating bone marrow derived endothelial progenitor (ECPs) and endothelial cells (CECs) contribute to neoangiogenesis in a process termed vasculogenesis. CECs can be detected in the blood of cancer patients and increased numbers are related to tumor progression. CECs and EPCs express endothelial cell surface markers as CD144 (VE-Cadherin) and VEGFR-2. Sprouting of new lymphatics from the preexisting lymphatic vessels has been described in solid tumors. Circulating lymphatic endothelial progenitor cells expressing CD133 and VEGFR3 were shown to differentiate into LYVE+ lymphatic endothelial cells (LECs) in vitro. Recently integration of circulating lymphatic endothelial progenitor cells in lymphatic neovessels was demonstrated in vivo. Therfore a distinct mechanism similar to vasculogenesis exists in lymphangiogenesis. Goal of our study was to identify and characterize circulating lymphatic endothelial cells in cancer patients. Presence of lymphatic endothelial cells in the peripheral blood was investigated in 26 patients with metastatic cancer and 10 healthy individuals. Additionally PBMNCs from G-CSF mobilised peripheral blood were analyzed (n=5). By developing a sensitive immunocytochemical approach we could identify a novel population of circulating lymphatic endothelial cells (CLECs) in patients with metastatic cancer. CLECs were LYVE+ and could be detected in 16 of 26 patients (62%) with metastatic cancer and in 4 of 10 healthy subjects (40%). The mean number of lymphendothelial cells was significantly higher in cancer patients (8.8 cells/1x106 PBMNCs [range 0–131] vs. 0.3 cells/1x106 PBMNCs [range 0–2]; p=0.03). We additionally investigated if CLECs were mobilised from bone marrow upon stimulation with G-CSF. 60% of analysed PBMNCs from leukapheresis products contained low numbers of circulating lymphatic endothelial cells comparable to normal peripheral blood (0.3 cells/1x106 PBMNCs [range 0–1]). Consequently CLECs unlike CEPs are not mobilised after cytokine stimulation from bone marrow. To better characterize CLECs, co-expression of VEGFR3 and LYVE was analyzed. We found that 90% of LYVE+ cells were positive for VEGFR3 which is consistent with a LEC phenotype previously described. Coexpression of vascular endothelial specific cell adhesion molecule CD144 (VE-Cadherin) was determined on LYVE+ cells by two-colour immunofluorescence. LYVE+ cells were negative for VE-Cadherin consistent with their lymphatic nature. We investigated whether LYVE+ cells represented a differentiated or a progenitor phenotype by double staining for LYVE and CD34 (n=3). All LYVE+ cells were negative for the progenitor marker CD34 indicating a differentiated lymphendothelial phenotype. Macrophages posess the capacity to transdifferentiate into lymphatic endothelial cells. We investigated whether circulating LYVE+ cells expressed CD11b and found a subfraction with a mean of 19% expressing LYVE and CD11b probably representing this macrophage subpopulation (range 13–25%, n=3). In summary our data show significantly higher levels of LYVE+ circulating lymphendothelial cells in patients with metastatic cancer compared to healthy subjects. Further studies are needed to clarify the origin of the circulating LECs and to analyse their potential as surrogate marker for lymphangiogenesis in cancer patients.</jats:p> Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. Blood |
| doi_str_mv |
10.1182/blood.v108.11.3947.3947 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA4LjExLjM5NDcuMzk0Nw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA4LjExLjM5NDcuMzk0Nw |
| institution |
DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
American Society of Hematology, 2006 |
| imprint_str_mv |
American Society of Hematology, 2006 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
loges2006identificationofcirculatinglymphendothelialcellsinthebloodofpatientswithsolidtumors |
| publishDateSort |
2006 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_unstemmed |
Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_full |
Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_fullStr |
Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_full_unstemmed |
Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_short |
Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_sort |
identification of circulating lymphendothelial cells in the blood of patients with solid tumors. |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood.v108.11.3947.3947 |
| publishDate |
2006 |
| physical |
3947-3947 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Angiogenesis and lymphangiogenesis promote tumor growth and metastasis. In addition to vessel sprouting circulating bone marrow derived endothelial progenitor (ECPs) and endothelial cells (CECs) contribute to neoangiogenesis in a process termed vasculogenesis. CECs can be detected in the blood of cancer patients and increased numbers are related to tumor progression. CECs and EPCs express endothelial cell surface markers as CD144 (VE-Cadherin) and VEGFR-2. Sprouting of new lymphatics from the preexisting lymphatic vessels has been described in solid tumors. Circulating lymphatic endothelial progenitor cells expressing CD133 and VEGFR3 were shown to differentiate into LYVE+ lymphatic endothelial cells (LECs) in vitro. Recently integration of circulating lymphatic endothelial progenitor cells in lymphatic neovessels was demonstrated in vivo. Therfore a distinct mechanism similar to vasculogenesis exists in lymphangiogenesis. Goal of our study was to identify and characterize circulating lymphatic endothelial cells in cancer patients. Presence of lymphatic endothelial cells in the peripheral blood was investigated in 26 patients with metastatic cancer and 10 healthy individuals. Additionally PBMNCs from G-CSF mobilised peripheral blood were analyzed (n=5). By developing a sensitive immunocytochemical approach we could identify a novel population of circulating lymphatic endothelial cells (CLECs) in patients with metastatic cancer. CLECs were LYVE+ and could be detected in 16 of 26 patients (62%) with metastatic cancer and in 4 of 10 healthy subjects (40%). The mean number of lymphendothelial cells was significantly higher in cancer patients (8.8 cells/1x106 PBMNCs [range 0–131] vs. 0.3 cells/1x106 PBMNCs [range 0–2]; p=0.03). We additionally investigated if CLECs were mobilised from bone marrow upon stimulation with G-CSF. 60% of analysed PBMNCs from leukapheresis products contained low numbers of circulating lymphatic endothelial cells comparable to normal peripheral blood (0.3 cells/1x106 PBMNCs [range 0–1]). Consequently CLECs unlike CEPs are not mobilised after cytokine stimulation from bone marrow. To better characterize CLECs, co-expression of VEGFR3 and LYVE was analyzed. We found that 90% of LYVE+ cells were positive for VEGFR3 which is consistent with a LEC phenotype previously described. Coexpression of vascular endothelial specific cell adhesion molecule CD144 (VE-Cadherin) was determined on LYVE+ cells by two-colour immunofluorescence. LYVE+ cells were negative for VE-Cadherin consistent with their lymphatic nature. We investigated whether LYVE+ cells represented a differentiated or a progenitor phenotype by double staining for LYVE and CD34 (n=3). All LYVE+ cells were negative for the progenitor marker CD34 indicating a differentiated lymphendothelial phenotype. Macrophages posess the capacity to transdifferentiate into lymphatic endothelial cells. We investigated whether circulating LYVE+ cells expressed CD11b and found a subfraction with a mean of 19% expressing LYVE and CD11b probably representing this macrophage subpopulation (range 13–25%, n=3). In summary our data show significantly higher levels of LYVE+ circulating lymphendothelial cells in patients with metastatic cancer compared to healthy subjects. Further studies are needed to clarify the origin of the circulating LECs and to analyse their potential as surrogate marker for lymphangiogenesis in cancer patients.</jats:p> |
| container_issue |
11 |
| container_start_page |
3947 |
| container_title |
Blood |
| container_volume |
108 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792322133889646601 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:13:03.551Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Identification+of+Circulating+Lymphendothelial+Cells+in+the+Blood+of+Patients+with+Solid+Tumors.&rft.date=2006-11-16&genre=article&issn=1528-0020&volume=108&issue=11&spage=3947&epage=3947&pages=3947-3947&jtitle=Blood&atitle=Identification+of+Circulating+Lymphendothelial+Cells+in+the+Blood+of+Patients+with+Solid+Tumors.&aulast=Fiedler&aufirst=Walter&rft_id=info%3Adoi%2F10.1182%2Fblood.v108.11.3947.3947&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792322133889646601 |
| author | Loges, Sonja, Suhrbier, Karin, Otten, Jasmin, Riethdorf, Sabine, Schuch, Gunter, Pantel, Klaus, Bokemeyer, Carsten, Fiedler, Walter |
| author_facet | Loges, Sonja, Suhrbier, Karin, Otten, Jasmin, Riethdorf, Sabine, Schuch, Gunter, Pantel, Klaus, Bokemeyer, Carsten, Fiedler, Walter, Loges, Sonja, Suhrbier, Karin, Otten, Jasmin, Riethdorf, Sabine, Schuch, Gunter, Pantel, Klaus, Bokemeyer, Carsten, Fiedler, Walter |
| author_sort | loges, sonja |
| container_issue | 11 |
| container_start_page | 3947 |
| container_title | Blood |
| container_volume | 108 |
| description | <jats:title>Abstract</jats:title> <jats:p>Angiogenesis and lymphangiogenesis promote tumor growth and metastasis. In addition to vessel sprouting circulating bone marrow derived endothelial progenitor (ECPs) and endothelial cells (CECs) contribute to neoangiogenesis in a process termed vasculogenesis. CECs can be detected in the blood of cancer patients and increased numbers are related to tumor progression. CECs and EPCs express endothelial cell surface markers as CD144 (VE-Cadherin) and VEGFR-2. Sprouting of new lymphatics from the preexisting lymphatic vessels has been described in solid tumors. Circulating lymphatic endothelial progenitor cells expressing CD133 and VEGFR3 were shown to differentiate into LYVE+ lymphatic endothelial cells (LECs) in vitro. Recently integration of circulating lymphatic endothelial progenitor cells in lymphatic neovessels was demonstrated in vivo. Therfore a distinct mechanism similar to vasculogenesis exists in lymphangiogenesis. Goal of our study was to identify and characterize circulating lymphatic endothelial cells in cancer patients. Presence of lymphatic endothelial cells in the peripheral blood was investigated in 26 patients with metastatic cancer and 10 healthy individuals. Additionally PBMNCs from G-CSF mobilised peripheral blood were analyzed (n=5). By developing a sensitive immunocytochemical approach we could identify a novel population of circulating lymphatic endothelial cells (CLECs) in patients with metastatic cancer. CLECs were LYVE+ and could be detected in 16 of 26 patients (62%) with metastatic cancer and in 4 of 10 healthy subjects (40%). The mean number of lymphendothelial cells was significantly higher in cancer patients (8.8 cells/1x106 PBMNCs [range 0–131] vs. 0.3 cells/1x106 PBMNCs [range 0–2]; p=0.03). We additionally investigated if CLECs were mobilised from bone marrow upon stimulation with G-CSF. 60% of analysed PBMNCs from leukapheresis products contained low numbers of circulating lymphatic endothelial cells comparable to normal peripheral blood (0.3 cells/1x106 PBMNCs [range 0–1]). Consequently CLECs unlike CEPs are not mobilised after cytokine stimulation from bone marrow. To better characterize CLECs, co-expression of VEGFR3 and LYVE was analyzed. We found that 90% of LYVE+ cells were positive for VEGFR3 which is consistent with a LEC phenotype previously described. Coexpression of vascular endothelial specific cell adhesion molecule CD144 (VE-Cadherin) was determined on LYVE+ cells by two-colour immunofluorescence. LYVE+ cells were negative for VE-Cadherin consistent with their lymphatic nature. We investigated whether LYVE+ cells represented a differentiated or a progenitor phenotype by double staining for LYVE and CD34 (n=3). All LYVE+ cells were negative for the progenitor marker CD34 indicating a differentiated lymphendothelial phenotype. Macrophages posess the capacity to transdifferentiate into lymphatic endothelial cells. We investigated whether circulating LYVE+ cells expressed CD11b and found a subfraction with a mean of 19% expressing LYVE and CD11b probably representing this macrophage subpopulation (range 13–25%, n=3). In summary our data show significantly higher levels of LYVE+ circulating lymphendothelial cells in patients with metastatic cancer compared to healthy subjects. Further studies are needed to clarify the origin of the circulating LECs and to analyse their potential as surrogate marker for lymphangiogenesis in cancer patients.</jats:p> |
| doi_str_mv | 10.1182/blood.v108.11.3947.3947 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA4LjExLjM5NDcuMzk0Nw |
| imprint | American Society of Hematology, 2006 |
| imprint_str_mv | American Society of Hematology, 2006 |
| institution | DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T11:13:03.551Z |
| match_str | loges2006identificationofcirculatinglymphendothelialcellsinthebloodofpatientswithsolidtumors |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 3947-3947 |
| publishDate | 2006 |
| publishDateSort | 2006 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Loges, Sonja Suhrbier, Karin Otten, Jasmin Riethdorf, Sabine Schuch, Gunter Pantel, Klaus Bokemeyer, Carsten Fiedler, Walter 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v108.11.3947.3947 <jats:title>Abstract</jats:title> <jats:p>Angiogenesis and lymphangiogenesis promote tumor growth and metastasis. In addition to vessel sprouting circulating bone marrow derived endothelial progenitor (ECPs) and endothelial cells (CECs) contribute to neoangiogenesis in a process termed vasculogenesis. CECs can be detected in the blood of cancer patients and increased numbers are related to tumor progression. CECs and EPCs express endothelial cell surface markers as CD144 (VE-Cadherin) and VEGFR-2. Sprouting of new lymphatics from the preexisting lymphatic vessels has been described in solid tumors. Circulating lymphatic endothelial progenitor cells expressing CD133 and VEGFR3 were shown to differentiate into LYVE+ lymphatic endothelial cells (LECs) in vitro. Recently integration of circulating lymphatic endothelial progenitor cells in lymphatic neovessels was demonstrated in vivo. Therfore a distinct mechanism similar to vasculogenesis exists in lymphangiogenesis. Goal of our study was to identify and characterize circulating lymphatic endothelial cells in cancer patients. Presence of lymphatic endothelial cells in the peripheral blood was investigated in 26 patients with metastatic cancer and 10 healthy individuals. Additionally PBMNCs from G-CSF mobilised peripheral blood were analyzed (n=5). By developing a sensitive immunocytochemical approach we could identify a novel population of circulating lymphatic endothelial cells (CLECs) in patients with metastatic cancer. CLECs were LYVE+ and could be detected in 16 of 26 patients (62%) with metastatic cancer and in 4 of 10 healthy subjects (40%). The mean number of lymphendothelial cells was significantly higher in cancer patients (8.8 cells/1x106 PBMNCs [range 0–131] vs. 0.3 cells/1x106 PBMNCs [range 0–2]; p=0.03). We additionally investigated if CLECs were mobilised from bone marrow upon stimulation with G-CSF. 60% of analysed PBMNCs from leukapheresis products contained low numbers of circulating lymphatic endothelial cells comparable to normal peripheral blood (0.3 cells/1x106 PBMNCs [range 0–1]). Consequently CLECs unlike CEPs are not mobilised after cytokine stimulation from bone marrow. To better characterize CLECs, co-expression of VEGFR3 and LYVE was analyzed. We found that 90% of LYVE+ cells were positive for VEGFR3 which is consistent with a LEC phenotype previously described. Coexpression of vascular endothelial specific cell adhesion molecule CD144 (VE-Cadherin) was determined on LYVE+ cells by two-colour immunofluorescence. LYVE+ cells were negative for VE-Cadherin consistent with their lymphatic nature. We investigated whether LYVE+ cells represented a differentiated or a progenitor phenotype by double staining for LYVE and CD34 (n=3). All LYVE+ cells were negative for the progenitor marker CD34 indicating a differentiated lymphendothelial phenotype. Macrophages posess the capacity to transdifferentiate into lymphatic endothelial cells. We investigated whether circulating LYVE+ cells expressed CD11b and found a subfraction with a mean of 19% expressing LYVE and CD11b probably representing this macrophage subpopulation (range 13–25%, n=3). In summary our data show significantly higher levels of LYVE+ circulating lymphendothelial cells in patients with metastatic cancer compared to healthy subjects. Further studies are needed to clarify the origin of the circulating LECs and to analyse their potential as surrogate marker for lymphangiogenesis in cancer patients.</jats:p> Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. Blood |
| spellingShingle | Loges, Sonja, Suhrbier, Karin, Otten, Jasmin, Riethdorf, Sabine, Schuch, Gunter, Pantel, Klaus, Bokemeyer, Carsten, Fiedler, Walter, Blood, Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors., Cell Biology, Hematology, Immunology, Biochemistry |
| title | Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_full | Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_fullStr | Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_full_unstemmed | Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_short | Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| title_sort | identification of circulating lymphendothelial cells in the blood of patients with solid tumors. |
| title_unstemmed | Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors. |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood.v108.11.3947.3947 |